Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | DTYMK | P23919 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 4/20 | 0.34 |
| ▸ | FNTB | P49356 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15888923 | 0.82 | GRM5 (0.34) | SCN9APOLBGRM5GRM1GPR119 | |
| SCHEMBL2447629 | 0.82 | GRM5 (0.37) | SCN9APOLBGRM5GRM1GPR119 | |
| SCHEMBL245192 | 0.82 | GRM5 (0.37) | SCN9APOLBGRM5GRM1GPR119 | |
| SCHEMBL27482569 | 0.80 | KLK7 (0.38) | SCN9APOLB | |
| SCHEMBL4706811 | 0.80 | KLK7 (0.38) | SCN9APOLB | |
| SCHEMBL15999868 | 0.80 | POLB (0.40) | SCN9APOLBGRM5GRM1GPR119 | |
| SCHEMBL31654621 | 0.74 | POLB (0.47) | POLBGRM5GRM1GPR119DTYMK | |
| SCHEMBL25889533 | 0.74 | POLB (0.47) | POLBGRM5GRM1GPR119DTYMK | |
| SCHEMBL14199221 | 0.74 | ELANE (0.44) | GPR119 | |
| SCHEMBL9924398 | 0.74 | ELANE (0.44) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1221445-B1 | PENTACYCLIC TAXANE COMPOUNDS | DAIICHI SANKYO CO LTD (JP) | 2008-08-20 | — | — | EP | disclosed |